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Snake venoms have been used as antineoplastic
substances in several experimental models. We de-
monstrated in previous studies that Bothrops jarar-
aca venom (BjV) induces inhibition of Ehrlich ascites
tumor (EAT) growth accompanied by an increase of
mononuclear (MN) leukocytes in all groups inocu-
lated with EAT and/or venom. The objective of the
present study was to characterize the subpopulations
of MN leukocytes involved in the inhibition of EAT
growth by treatment with BjV. Swiss mice were
inoculated with 1.0/10
3 EAT cells by the intraper-
itoneal route and treated with 0.4 mg/kg of BjV by the
same route (Group TV). Treatment was started 24 h
after tumor cell inoculation and consisted of five
intraperitoneal injections performed at 72 h inter-
vals. After 2, 8 and 14 days, groups of animals were
sacrificed and the number of B, TCD4 and TCD8
lymphocytes, macrophages and natural killer cells
present in the peritoneal cavity was determined by
flow cytometry. The control group consisted of
animals inoculated with EAT and treated with 0.1 ml
of saline under the same conditions as the experi-
mental group (Group T). Two additional control
groups consisted of animals not inoculated with
EAT and treated with saline or venom. Data were
analyzed statistically by the Kruskal 
/Wallis non-
parametric test for independent samples. On the
2nd and 8th day we observed a difference between
groups T and TV (group T /group TV) for all cell
types, except natural killer cells, that only differed on
the 2nd day. However, on the 14th day there was no
difference in MN cells among groups. These data
suggest that the inhibition of EAT is related to the
toxic action of BjV on tumor cells and/or to the
proteolytic effect of the venom on the mediators
produced by the cells for growth modulation.
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Introduction
Snake venoms have been used as antitumor sub-
stances in several experimental protocols.
1 In pre-
vious studies we demonstrated that the venom of
Crotalus durissus terrificus and Bothrops jararaca
venom (BjV) have an important inhibitory effect on
the growth of Ehrlich ascites tumor (EAT).
2,3
The inhibition of EAT growth in the animals treated
with BjV is accompanied by alteration in the cytokine
profile in the peritoneal cavity of the animals
4 and by
an increase of mononuclear (MN) leukocytes in all
groups inoculated with EAT and/or venom.
3
Although no difference was detected in the increased
quantity of MN cells in the peritoneal cavity of these
groups, we do not rule out the possibility that
different subpopulations may be involved in tumor
growth inhibition.
There are no reports in the literature that demon-
strate the cell types involved in the inhibition of EAT
growth. This aspect is important because it will allow
one to infer whether the inhibition of the tumor
growth is associated with a certain cell population
and/or with the direct effect of the venom on these
cells. The aim of the present study was determine the
cell subpopulation involved in EAT growth inhibition
after treatment with BjV.
Materials and methods
Animals
Male Swiss male mice, 4 /6 weeks old, from our own
animal facilities were used throughout the experi-
ment.
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BjV was obtained from snakes maintained in captivity
at The Center for the Study of Venoms and Venomous
Animals of Sa ˜o Paulo State University, Brazil. Newly
extracted venom was centrifuged for 10 min at 200
 /g, filtered through a GSWP00250 Millipore filter,
and lyophilized. The lethal dose 50 (LD50) for this
venom was previously determined as 2.4 mg/kg of
animal weight. The venom was stored at 48C during
the experiment. Preliminary protocols have shown
that 0.4 mg/kg of BjV is effective for tumor growth
inhibition.
Ehrlich ascites tumor
The tumor was maintained in Swiss mice in the ascitic
form. Tumor cells were collected by aspiration with a
Pasteur pipette, centrifuged for 10 min at 200 /g,
and washed twice with phosphate-buffered saline
(pH 7.2). Cell viability was evaluated by the Trypan
blue exclusion test, and only cell suspensions that
presented more than 95% viability were used.
Peritoneal cells
Cells were harvested by peritoneal washing using 3
ml of sterile phosphate-buffered saline. The number
of cells was determined with a hemocytometer.
Differential counts were performed on fixed and
stained cell suspensions (0.5% crystal violet dissolved
in 30% acetic acid).
Analysis of the MN leukocyte subpopulations by
flow cytometry
In this protocol we evaluated the number of five
types of MN leukocytes: TCD4, TCD8 and B lympho-
cytes (CD22), macrophages (Mac3), and natural killer
(NK1.1) cells. The total number of cells present in the
peritoneal cavity was determined with a hemocyt-
ometer and the number of MN leukocytes was
determined by flow cytometry. The peritoneal sus-
pensions were adjusted to 1 /10
6 cells/ml, and 100
ml of this solution were incubated with a monoclonal
antibody labeled with fluorescein isothiocyanate
(FITC). The protocols, antibodies and reagents em-
ployed were as per the manufacturer’s recommenda-
tions (Pharmigen). The percentage of labeled cells
was obtained by analysis of 10,000 cells/sample with
a FACSCalibur flow cytometer (Becton-Dickinson,
Palo Alto, CA, USA) using the Cell-Quest software.
Experiment design
Mice were inoculated by the intraperitoneal route
(i.p.) with 1 /10
3 EAT cells and treated with BjV (0.4
mg/kg) or saline (0.1 ml, i.p.). The first BjV dose was
administered 24 h after tumor implantation and
repeated five times at 72 h intervals. Additional
non-tumor-bearing control groups were treated
with BjV or saline according to the same protocol as
used for the experimental groups. Ten animals from
each group were sacrificed by sulfur ether inhalation
2, 8, and 14 days after EAT implantation, and the MN
leukocyte number present in the peritoneal cavity
was evaluated by flow cytometry.
Statistical analysis
Data were analyzed statistically by the Kruskall /
Wallis test or by analysis of variance for independent
sets, and by the Tukey or Student /Newman /Keuls
test for differences between groups, with the level of
significance set at 5%.
Results
Analysis of the results obtained on the 2nd and 8th
day of tumor growth showed that the group inocu-
lated with tumor and treated with BjV presented a
smaller amount of TCD4, TCD8 and B lymphocytes,
and of macrophages, compared with the group
inoculated with EAT cells and not treated with
venom. For natural killer cells, a decrease was
observed only on the 2nd day. However, on the
14th day the amounts of all cell types were similar in
the groups inoculated with tumor, whether or not
they were treated with venom (Table 1).
We also observed that the group not inoculated
with EAT cells and treated with BjV showed a
reduction in the number of TCD4 lymphocyte, B
lymphocyte, macrophage and tural killer cells on the
2nd day of tumor growth, an increase in TCD8 cells
on the 8th day and an increase in macrophages on
the 14th day compared the control group inoculated
with saline (Table 1).
Discussion
The present study was carried out to characterize the
cell subpopulation involved in the evolution of EAT
treated with BjV, because in a previous study we
demonstrated that treatment with this venom induces
an increase in MN leukocytes in all groups inoculated
with EAT cells and/or venom compared with the
saline control group.
3 However, in this previous
study, we did not detect a difference in the amount
of MN leukocytes present in the peritoneal cavity
peritoneal among the groups inoculated with tumor
and/or venom. Nevertheless, we did not exclude the
possibility that different subpopulations could be
involved in the inhibition of tumor growth. The
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effective participation in the elimination of tumor
cells,
5 13 and therefore it would be important to
evaluate the participation of this cell type in the
evolution of EAT.
However, analysis of the results obtained in this
stage of the study showed that there was no
difference in the amounts of TCD4 lymphocytes,
TCD lymphocytes, B lymphocytes, macrophage and
natural killer cells between the groups inoculated
with tumor, treated or not with BjV. Thus, we believe
that tumor growth inhibition is related to a direct
effect of the poison on tumoral cells and/or for to the
proteolytic effect of the venom on the mediators
produced by the tumor cells for growth modulation.
These data agree with the results reported by Rizzo
and Tuchiya
14 and Silva et al.,
3 who showed a toxic
effect of BjV both on tumor cells and on peritoneal
cells.
Analysis of the results obtained by evaluation of
the MN leukocyte subpopulations during this stage of
the study showed that, 24 h after the first venom
inoculation (2nd day of tumor growth), the numbers
of all cell types studied (i.e. TCD4 lymphocytes,
TCD8 lymphocytes, B lymphocytes, macrophages
and natural killer cells) were significantly reduced
compared with the control group inoculated with
saline, indicating a toxic effect of the venom on these
cells.
The present results did not show an effective
participation of MN cell in the process of tumor
growth inhibition observed in the previous experi-
ments. These results strongly suggest that this inhibi-
tion is related to the direct effect of the venom on
tumor cells and/or to the proteolytic effect of the
venom on the mediators produced by the tumor cells
for growth modulation.
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